Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

Type
Public
HQ
Gaithersburg, US
Founded
1998
Size (employees)
1,098 (est)-15%
Emergent Biosolutions was founded in 1998 and is headquartered in Gaithersburg, US

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Washington, Lansing, Winnipeg and in 5 other locations
Gaithersburg, US (HQ)
400 Professional Dr
Baltimore, US
1111 S Paca St
Seattle, US
1050 2401 4th Ave
Richmond, GB
Kew Rd
Gaithersburg, US
400 400 Professional Dr
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Winnipeg, CA
155 Innovation Dr
Lansing, US
3500 N Martin Luther King Jr Blvd
Gaithersburg, US
300 Professional Dr
Washington, US
1225 1455 Pennsylvania Ave Nw

Emergent Biosolutions Data and Metrics

Emergent Biosolutions Financial Metrics

Emergent Biosolutions's revenue was reported to be $488.8 m in FY, 2016 which is a 7% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

488.8 m

Revenue growth (FY, 2015 - FY, 2016), %

(7%)

Net income (FY, 2016)

51.8 m

EBIT (FY, 2016)

105.5 m

Market capitalization (23-May-2017)

1.2 b

Closing share price (23-May-2017)

29.5

Cash (31-Dec-2016)

271.5 m
Emergent Biosolutions's current market capitalization is $1.2 b.
Numbers are in $, USDFY, 2013FY, 2015FY, 2016

Revenue

312.7 m522.8 m488.8 m

Revenue growth, %

(7%)

Cost of goods sold

62.1 m

Gross profit

250.6 m398.5 m

Gross profit Margin, %

80%76%

EBIT

42.8 m96 m105.5 m

EBIT margin, %

14%18%22%

Interest income

139 k572 k1.1 m

Pre tax profit

43.4 m89.8 m

Net Income

30.3 m62.9 m51.8 m
Numbers are in $, USDFY, 2013FY, 2015FY, 2016

Cash

179.3 m312.8 m271.5 m

Accounts Receivable

60.6 m120.8 m138.5 m

Inventories

14.6 m76.9 m74 m

Current Assets

273.1 m538.6 m510.2 m

PP&E

264.2 m331.9 m376.4 m

Goodwill

14 m

Total Assets

626.6 m1 b970.1 m

Accounts Payable

27.5 m46 m34.6 m

Current Liabilities

56.7 m99.6 m105.9 m

Additional Paid-in Capital

247.6 m318 m352.4 m

Retained Earnings

251.5 m351.1 m254.5 m

Total Equity

489.2 m660 m596.2 m

Financial Leverage

1.3 x1.6 x1.6 x
Numbers are in $, USDFY, 2013FY, 2015FY, 2016

Net Income

30.3 m62.9 m51.8 m

Depreciation and Amortization

19 m

Accounts Receivable

35.5 m(64 m)(22 m)

Inventories

518 k(11 m)(9 m)

Accounts Payable

(551 k)4.7 m(14.8 m)

Cash From Operating Activities

97 m44.5 m53.5 m

Purchases of PP&E

(42 m)(44.8 m)(76.3 m)

Cash From Investing Activities

(67.9 m)(45.5 m)(76.3 m)

Cash From Financing Activities

8.6 m33.4 m(18.6 m)

Interest Paid

2.1 m7.8 m8.2 m

Income Taxes Paid

(7.2 m)(3.6 m)(4.6 m)
Y, 2016

Financial Leverage

1.6 x

Emergent Biosolutions Market Value History

Emergent Biosolutions Online and Social Media Presence

Emergent Biosolutions News and Updates

Emergent Biosolutions Company Life and Culture

You may also be interested in